215 related articles for article (PubMed ID: 31394715)
1. Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.
Iwata Y; Matsumura T
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31394715
[TBL] [Abstract][Full Text] [Related]
2. Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models.
Iwata Y; Wakabayashi S; Ito S; Kitakaze M
Lab Invest; 2020 Feb; 100(2):324-337. PubMed ID: 31896817
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy.
Matsumura T; Matsui M; Iwata Y; Asakura M; Saito T; Fujimura H; Sakoda S
Intern Med; 2018 Feb; 57(3):311-318. PubMed ID: 29093384
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models.
Iwata Y; Katanosaka Y; Arai Y; Shigekawa M; Wakabayashi S
Hum Mol Genet; 2009 Mar; 18(5):824-34. PubMed ID: 19050039
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of TRPV2 Channel Activation by NK-4, a Cryptocyanine Dye].
Koya-Miyata S; Kohno K; Morimoto T; Harashima A; Iwata Y; Ariyasu T
Yakugaku Zasshi; 2022 May; 142(5):535-546. PubMed ID: 35228454
[TBL] [Abstract][Full Text] [Related]
6. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy.
Iwata Y; Ohtake H; Suzuki O; Matsuda J; Komamura K; Wakabayashi S
Cardiovasc Res; 2013 Sep; 99(4):760-8. PubMed ID: 23786999
[TBL] [Abstract][Full Text] [Related]
7. Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model.
Iwata Y; Katayama Y; Okuno Y; Wakabayashi S
Oncotarget; 2018 Mar; 9(18):14042-14057. PubMed ID: 29581825
[TBL] [Abstract][Full Text] [Related]
8. TRPV2 channel-based therapies in the cardiovascular field. Molecular underpinnings of clinically relevant therapies.
O'Connor B; Robbins N; Koch SE; Rubinstein J
Prog Biophys Mol Biol; 2021 Jan; 159():118-125. PubMed ID: 32565182
[TBL] [Abstract][Full Text] [Related]
9. Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study.
Matsumura T; Hashimoto H; Sekimizu M; Saito AM; Motoyoshi Y; Nakamura A; Kuru S; Fukudome T; Segawa K; Takahashi T; Tamura T; Komori T; Watanabe C; Asakura M; Kimura K; Iwata Y
Orphanet J Rare Dis; 2022 May; 17(1):201. PubMed ID: 35578298
[TBL] [Abstract][Full Text] [Related]
10. TRPV2 channel as a possible drug target for the treatment of heart failure.
Iwata Y; Ito S; Wakabayashi S; Kitakaze M
Lab Invest; 2020 Feb; 100(2):207-217. PubMed ID: 31857697
[TBL] [Abstract][Full Text] [Related]
11. Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage.
Lorin C; Vögeli I; Niggli E
Cardiovasc Res; 2015 Apr; 106(1):153-62. PubMed ID: 25616416
[TBL] [Abstract][Full Text] [Related]
12. Stretch-activated TRPV2 channels: Role in mediating cardiopathies.
Aguettaz E; Bois P; Cognard C; Sebille S
Prog Biophys Mol Biol; 2017 Nov; 130(Pt B):273-280. PubMed ID: 28546113
[TBL] [Abstract][Full Text] [Related]
13. TRP channels in normal and dystrophic skeletal muscle.
Gailly P
Curr Opin Pharmacol; 2012 Jun; 12(3):326-34. PubMed ID: 22349418
[TBL] [Abstract][Full Text] [Related]
14. Axial stretch-dependent cation entry in dystrophic cardiomyopathy: Involvement of several TRPs channels.
Aguettaz E; Lopez JJ; Krzesiak A; Lipskaia L; Adnot S; Hajjar RJ; Cognard C; Constantin B; Sebille S
Cell Calcium; 2016 Apr; 59(4):145-155. PubMed ID: 26803937
[TBL] [Abstract][Full Text] [Related]
15. Study Protocol for a Multicenter, Open-Label, Single-Arm Study of Tranilast for Cardiomyopathy of Muscular Dystrophy.
Matsumura T; Hashimoto H; Sekimizu M; Saito AM; Iwata Y; Asakura M; Kimura K; Tamura T; Funato M; Segawa K; Ogata K; Nakajima T
Kurume Med J; 2021 Jul; 66(2):121-126. PubMed ID: 34135201
[TBL] [Abstract][Full Text] [Related]
16. Becker muscular dystrophy with early manifestation of left heart failure.
Miyashita H; Ikeda U; Shimada K; Natsume T; Arahata K
Intern Med; 1993 May; 32(5):408-11. PubMed ID: 8400504
[TBL] [Abstract][Full Text] [Related]
17. Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast.
Takahashi C; Oishi M; Iwata Y; Maekawa K; Matsumura T
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768491
[TBL] [Abstract][Full Text] [Related]
18. Reply to "The Effects of Tranilast on Cardiomyopathy in Becker Muscular Dystrophy Requires Profound Cardiac and Neurologic Evaluations".
Matsumura T; Iwata Y; Asakura M
Intern Med; 2018 Jul; 57(14):2101-2102. PubMed ID: 29491287
[No Abstract] [Full Text] [Related]
19. Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease.
Robbins N; Koch SE; Rubinstein J
Transl Res; 2013 Jun; 161(6):469-76. PubMed ID: 23453732
[TBL] [Abstract][Full Text] [Related]
20. Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy.
Zhu X; Wheeler MT; Hadhazy M; Lam MY; McNally EM
FASEB J; 2002 Jul; 16(9):1096-8. PubMed ID: 12039854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
